18β-Glycyrrhetinic acid

Name: 18β-Glycyrrhetinic acid
Brand: MedChemExpress
SKU: HY-N0180
Rating: 5.0 (14 reviews)

Cat. No.: HY-N0180 Purity: 99.88%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

18β-Glycyrrhetinic acid is the major bioactive component of Glycyrrhiza uralensis and possesses anti-ulcerative, anti-inflammatory and antiproliferative properties.

For research use only. We do not sell to patients.

CAS No. : 471-53-4

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	In-stock	Estimated Time of Arrival: December 31
10 g	In-stock	Estimated Time of Arrival: December 31
50 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 14 publication(s) in Google Scholar

Other Forms of 18β-Glycyrrhetinic acid:

18α-Glycyrrhetinic acid In-stock
18β-Glycyrrhetinic acid (Standard) In-stock
18β-Glycyrrhetinic acid-d₃ Get quote

14 Publications Citing Use of MCE 18β-Glycyrrhetinic acid

Cell Proliferation/Viability Assay

Bio/Physico-chemical Assay

Flow Cytometry

Cell Migration/Invasion Assay

RT-PCR

: 18β-Glycyrrhetinic acid purchased from MedChemExpress. Usage Cited in: J Hazard Mater Lett. 2025 Nov.; Chemical inhibition of PCP sulfonation was achieved through the application of different inhibitors, including DCNP (0.5 μM), nimesulide (10 μM), ibuprofen (1 mM), quercetin (10 μM), salbutamol (5 mM), 18β-Glycyrrhetinic acid (GA, 30 μM) and DHEA(30 μM) in pooled human liver cytosol incubations.

: 18β-Glycyrrhetinic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Mar;11(11):e2305260. [Abstract]; Immunoblots (top) and quantification (bottom) of SHMT2 and ADAM10 in SH‐SY5Y cells treated with KEN, in the absence or presence of SHMT2 inhibitor 18β-Glycyrrhetinic acid (GA, 100 µM for 48 h) or the 5′UTR‐dependent ADAM10 enhancer Cosmosiin, respectively (n = 3).

: 18β-Glycyrrhetinic acid purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Nov:134:155937. [Abstract]; 18β-Glycyrrhetinic acid (0.01-10 μM). Dose-response curves of celastrol and other control molecules on CML cell lines K562 and KBM7 after 72 h treatment.

: 18β-Glycyrrhetinic acid purchased from MedChemExpress. Usage Cited in: World J Gastroenterol. 2023 Jun 21;29(23):3622-3644.; Effect of 18β-glycyrrhetinic acid (18β-GRA) on cell viability of AGS cells and HGC-27 cells; IC50 value of AGS and HGC-27 cells were treated with 18β-GRA for 24, 48 and 72 h.

: 18β-Glycyrrhetinic acid purchased from MedChemExpress. Usage Cited in: World J Gastroenterol. 2023 Jun 21;29(23):3622-3644.; Effect of 18β-glycyrrhetinic acid (18β-GRA, 0-90 μmol/L) on AGS cells cycle; Statistical results of AGS cell cycle.

: 18β-Glycyrrhetinic acid purchased from MedChemExpress. Usage Cited in: World J Gastroenterol. 2023 Jun 21;29(23):3622-3644.; Effect of 18β-glycyrrhetinic acid (18β-GRA, 0-135 μmol/L) on HGC-27 cells cycle; Statistical results of HGC-27 cells cycle.

: 18β-Glycyrrhetinic acid purchased from MedChemExpress. Usage Cited in: World J Gastroenterol. 2023 Jun 21;29(23):3622-3644.; Effect of 18β-glycyrrhetinic acid (18β-GRA, 0-90 μmol/L) on the wound healing of AGS cells; Statistical results of the wound healing in AGS cells.

: 18β-Glycyrrhetinic acid purchased from MedChemExpress. Usage Cited in: World J Gastroenterol. 2023 Jun 21;29(23):3622-3644.; Effect of 18β-glycyrrhetinic acid (18β-GRA, 0-135 μmol/L) on wound healing of HGC-27 cells; Statistical results of the wound healing in HGC-27 cells.

: 18β-Glycyrrhetinic acid purchased from MedChemExpress. Usage Cited in: World J Gastroenterol. 2023 Jun 21;29(23):3622-3644.; Effect of 18β-glycyrrhetinic acid (18β-GRA) with different concentrations of miR-345-5p expression level in AGS cells and HGC-27 cells.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

18β-Glycyrrhetinic acid is the major bioactive component of Glycyrrhiza uralensis and possesses anti-ulcerative, anti-inflammatory and antiproliferative properties.

Cellular Effect

Cell Line	Type	Value	Description	References
1A9	ED₅₀	> 21 μM Compound: 1, GA	Cytotoxicity against human 1A9 cells Cytotoxicity against human 1A9 cells	[PMID: 17591444]
4T1	IC₅₀	174.5 μM Compound: 1; GA	Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
518A2	EC₅₀	83.92 μM Compound: GA	Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
518A2	EC₅₀	> 30 μM Compound: 3	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 28033541]
518A2	IC₅₀	83.92 μM Compound: GA	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 20932766]
518A2	IC₅₀	83.92 μM Compound: GA	Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
8505C	EC₅₀	86.5 μM Compound: GA	Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
8505C	EC₅₀	> 30 μM Compound: 3	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 28033541]
8505C	IC₅₀	86.5 μM Compound: GA	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 20932766]
8505C	IC₅₀	86.5 μM Compound: GA	Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
A-375	IC₅₀	98.14 μM Compound: 1; GA	Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
A-431	IC₅₀	79.58 μM Compound: GA	Cytotoxicity against human A431 cells after 96 hrs by SRB assay Cytotoxicity against human A431 cells after 96 hrs by SRB assay	[PMID: 20932766]
A2780	EC₅₀	> 30 μM Compound: 3	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 28033541]
A2780	EC₅₀	> 30 μM Compound: GA	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
A2780	IC₅₀	74.57 μM Compound: GA	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 20932766]
A2780	IC₅₀	74.57 μM Compound: GA	Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
A549	EC₅₀	82.76 μM Compound: GA	Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
A549	EC₅₀	> 30 μM Compound: 3	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 28033541]
A549	GI₅₀	61.2 μM Compound: 1, GA	Growth inhibition of human A549 cells by SRB assay Growth inhibition of human A549 cells by SRB assay	[PMID: 23122524]
A549	GI₅₀	> 100 μM Compound: 1, GA	Growth inhibition in apoptosis-resistant human A549 after 3 days by MTT assay Growth inhibition in apoptosis-resistant human A549 after 3 days by MTT assay	[PMID: 21888390]
A549	IC₅₀	36.15 μM Compound: GA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30528976]
A549	IC₅₀	78 μg/mL Compound: GA	Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by XTT assay Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by XTT assay	[PMID: 24461294]
A549	IC₅₀	82.76 μM Compound: GA	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 20932766]
A549	IC₅₀	82.76 μM Compound: GA	Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
A549	IC₅₀	84.25 μM Compound: GA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 29486954]
A549	IC₅₀	94.97 μM Compound: 1; GA	Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
A549	IC₅₀	> 100 μM Compound: GA	Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
A549	IC₅₀	> 200 μM Compound: 3; GA	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
A549	IC₅₀	> 30 μM Compound: GA	Inhibition of TNF-alpha induced NF-kappaB activation in human A549 cells after 7 hrs by Bright-Glo luciferase reporter gene assay Inhibition of TNF-alpha induced NF-kappaB activation in human A549 cells after 7 hrs by Bright-Glo luciferase reporter gene assay	[PMID: 30528976]
A549	IC₅₀	> 40 μM Compound: GA	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 31226654]
A549/TR	IC₅₀	99.85 μM Compound: 3; GA	Cytotoxicity against human A549/T cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549/T cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
B16-F10	GI₅₀	37 μM Compound: 1, GA	Growth inhibition in mouse B16F10 after 3 days by MTT assay Growth inhibition in mouse B16F10 after 3 days by MTT assay	[PMID: 21888390]
B16-F10	IC₅₀	138.8 μM Compound: 1; GA	Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
Bel-7402	IC₅₀	> 200 μM Compound: 3; GA	Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
Bel-7402	IC₅₀	> 50 μM Compound: GA	Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay	[PMID: 20932754]
Bel7402/5-FU	IC₅₀	69.77 μM Compound: 3; GA	Cytotoxicity against human Bel7402/5-FU cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human Bel7402/5-FU cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
DLD-1	IC₅₀	81.21 μM Compound: GA	Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay	[PMID: 20932766]
DLD-1	IC₅₀	81.21 μM Compound: GA	Cytotoxicity against human DLD1 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human DLD1 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
DU-145	ED₅₀	> 21 μM Compound: 1, GA	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 17591444]
DU-145	GI₅₀	64.9 μM Compound: 1, GA	Growth inhibition of human DU145 cells by SRB assay Growth inhibition of human DU145 cells by SRB assay	[PMID: 23122524]
ECV-304	IC₅₀	101 μM Compound: Glycyrrhetinic acid	Cytotoxicity against human ECV304 cells after 72 hrs by Hoechst 33258 staining based fluorescence assay Cytotoxicity against human ECV304 cells after 72 hrs by Hoechst 33258 staining based fluorescence assay	[PMID: 22503361]
ECV-304	IC₅₀	292 μM Compound: Glycyrrhetinic acid	Membranolytic activity in human ECV304 cells assessed as leakage of intracellular lactate dehydrogenase after 2 hrs by spectrophotometry Membranolytic activity in human ECV304 cells assessed as leakage of intracellular lactate dehydrogenase after 2 hrs by spectrophotometry	[PMID: 22503361]
Epidermoid carcinoma cell line	IC₅₀	>= 0.3 μM Compound: 18betaH-GA	Cytotoxicity against human Epidermoid carcinoma cell line Cytotoxicity against human Epidermoid carcinoma cell line	[PMID: 33383441]
FaDu	EC₅₀	> 30 μM Compound: GA	Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
FaDu	IC₅₀	84.55 μM Compound: GA	Cytotoxicity against human FADU cells after 96 hrs by SRB assay Cytotoxicity against human FADU cells after 96 hrs by SRB assay	[PMID: 20932766]
FaDu	IC₅₀	84.55 μM Compound: GA	Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
HCT-116	IC₅₀	78.83 μM Compound: GA	Cytotoxicity against human HCT116 cells after 96 hrs by SRB assay Cytotoxicity against human HCT116 cells after 96 hrs by SRB assay	[PMID: 20932766]
HCT-116	IC₅₀	78.83 μM Compound: GA	Cytotoxicity against human HCT116 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
HCT-116	IC₅₀	91.25 μM Compound: GA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29486954]
HCT-8	ED₅₀	19.5 μM Compound: 1, GA	Cytotoxicity against human HCT8 cells Cytotoxicity against human HCT8 cells	[PMID: 17591444]
HCT-8	IC₅₀	78.85 μM Compound: GA	Cytotoxicity against human HCT8 cells after 96 hrs by SRB assay Cytotoxicity against human HCT8 cells after 96 hrs by SRB assay	[PMID: 20932766]
HCT-8	IC₅₀	78.85 μM Compound: GA	Cytotoxicity against human HCT8 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HCT8 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
HEK293	IC₅₀	0.005 μM Compound: enoxolone	Inhibition of mouse 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay in presence of NADPH Inhibition of mouse 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay in presence of NADPH	[PMID: 18653260]
HEK293	IC₅₀	0.0086 μM Compound: Glycyrrhetinic acid	Inhibition of human 11beta HSD1 expressed in HEK293 cells assessed as assessed as inhibition of [1,2-(n)3H]cortisone to [3H]-cortisol after 60 mins by scintillation proximity assay Inhibition of human 11beta HSD1 expressed in HEK293 cells assessed as assessed as inhibition of [1,2-(n)3H]cortisone to [3H]-cortisol after 60 mins by scintillation proximity assay	[PMID: 21873057]
HEK293	IC₅₀	0.013 μM Compound: enoxolone	Inhibition of human 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay in presence of NADPH Inhibition of human 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay in presence of NADPH	[PMID: 18653260]
HEK293	IC₅₀	1.2 nM Compound: GA	Inhibition of human 11beta-HSD2 overexpressed in microsomal fraction of HEK293 cells using [3H]-cortisol as substrate by scintillation proximity assay in presence of NAD+ Inhibition of human 11beta-HSD2 overexpressed in microsomal fraction of HEK293 cells using [3H]-cortisol as substrate by scintillation proximity assay in presence of NAD+	[PMID: 25590374]
HEK293	IC₅₀	1.3 nM Compound: 1; GA	Inhibition of full-length human 11beta-HSD2 expressed in HEK293 microsomal fraction using [3H]cortisone as substrate after 2 hr by scintillation proximity assay Inhibition of full-length human 11beta-HSD2 expressed in HEK293 microsomal fraction using [3H]cortisone as substrate after 2 hr by scintillation proximity assay	[PMID: 28458137]
HEK293	IC₅₀	11.3 nM Compound: 1; GA	Inhibition of full-length human 11beta-HSD1 expressed in HEK293 microsomal fraction using [3H]cortisone as substrate after 2 hr by scintillation proximity assay Inhibition of full-length human 11beta-HSD1 expressed in HEK293 microsomal fraction using [3H]cortisone as substrate after 2 hr by scintillation proximity assay	[PMID: 28458137]
HEK293	IC₅₀	2 nM Compound: GA	Inhibition of mouse 11beta-HSD1 expressed in HEK293 cell microsomes assessed as inhibition of [3H]cortisone conversion to [3H]cortisol by scintillation proximity assay Inhibition of mouse 11beta-HSD1 expressed in HEK293 cell microsomes assessed as inhibition of [3H]cortisone conversion to [3H]cortisol by scintillation proximity assay	[PMID: 23747808]
HEK293	IC₅₀	257 nM Compound: 1, GA	Inhibition of human 11beta-HSD2 expressed in HEK293 cells assessed as conversion of [1,2,6,7-[3H]cortisol to cortisone after 10 mins by scintillation counting Inhibition of human 11beta-HSD2 expressed in HEK293 cells assessed as conversion of [1,2,6,7-[3H]cortisol to cortisone after 10 mins by scintillation counting	[PMID: 21376605]
HEK293	IC₅₀	257 nM Compound: GA	Inhibition of human recombinant 11beta-HSD2 expressed in HEK293 cells assessed as conversion of [1,2,6,7-3H]-cortisol to cortisone by scintillation counting Inhibition of human recombinant 11beta-HSD2 expressed in HEK293 cells assessed as conversion of [1,2,6,7-3H]-cortisol to cortisone by scintillation counting	[PMID: 20851614]
HEK293	IC₅₀	29.1 nM Compound: GA	Inhibition of human 11beta-HSD1 expressed in HEK293 cell microsomes assessed as inhibition of [3H]cortisone conversion to [3H]cortisol by scintillation proximity assay Inhibition of human 11beta-HSD1 expressed in HEK293 cell microsomes assessed as inhibition of [3H]cortisone conversion to [3H]cortisol by scintillation proximity assay	[PMID: 23747808]
HEK293	IC₅₀	29.1 nM Compound: GA	Inhibition of human 11beta-HSD1 overexpressed in microsomal fraction of HEK293 cells assessed as formation of [3H]-cortisol from [3H]-cortisone by scintillation proximity assay in presence of NADPH Inhibition of human 11beta-HSD1 overexpressed in microsomal fraction of HEK293 cells assessed as formation of [3H]-cortisol from [3H]-cortisone by scintillation proximity assay in presence of NADPH	[PMID: 25590374]
HEK293	IC₅₀	40.2 nM Compound: GA	Inhibition of mouse 11beta-HSD1 overexpressed in microsomal fraction of HEK293 cells assessed as formation of [3H]-cortisol from [3H]-cortisone by scintillation proximity assay in presence of NADPH Inhibition of mouse 11beta-HSD1 overexpressed in microsomal fraction of HEK293 cells assessed as formation of [3H]-cortisol from [3H]-cortisone by scintillation proximity assay in presence of NADPH	[PMID: 25590374]
HEK293	IC₅₀	778 nM Compound: 1, GA	Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [1,2-[3H]cortisone to cortisol after 10 mins by scintillation counting Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [1,2-[3H]cortisone to cortisol after 10 mins by scintillation counting	[PMID: 21376605]
HEK293	IC₅₀	778 nM Compound: GA	Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [1,2-3H]-cortisone to cortisol by scintillation counting Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [1,2-3H]-cortisone to cortisol by scintillation counting	[PMID: 20851614]
HEK293	IC₅₀	8.8 nM Compound: Glycyrrhetinic acid	Inhibition of human microsomal 11beta-HSD1 overexpressed in HEK293 cells using [3H]-cortisone as substrate assessed as formation of [3H]-cortisol using [3H]cortisone by scintillation proximity assay in presence of NADPH Inhibition of human microsomal 11beta-HSD1 overexpressed in HEK293 cells using [3H]-cortisone as substrate assessed as formation of [3H]-cortisol using [3H]cortisone by scintillation proximity assay in presence of NADPH	[PMID: 26936592]
HEK293	IC₅₀	9.4 nM Compound: Glycyrrhetinic acid	Inhibition of mouse microsomal 11beta-HSD1 overexpressed in HEK293 cells using [3H]-cortisone as substrate assessed as formation of [3H]-cortisol using [3H]cortisone by scintillation proximity assay in presence of NADPH Inhibition of mouse microsomal 11beta-HSD1 overexpressed in HEK293 cells using [3H]-cortisone as substrate assessed as formation of [3H]-cortisol using [3H]cortisone by scintillation proximity assay in presence of NADPH	[PMID: 26936592]
HL-60	IC₅₀	55.28 μM Compound: GA	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition after 72 hrs by trypan blue staining based cell counting assay Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition after 72 hrs by trypan blue staining based cell counting assay	[PMID: 31883490]
HL-60	IC₅₀	63.2 μM Compound: 2; Glycyrrhetic acid	Cytotoxicity against human HL60 cells Cytotoxicity against human HL60 cells	10.1039/C4MD00344F
HT-29	EC₅₀	80.09 μM Compound: GA	Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
HT-29	EC₅₀	> 30 μM Compound: 3	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 28033541]
HT-29	EC₅₀	> 30 μM Compound: GA	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
HT-29	IC₅₀	80.09 μM Compound: GA	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 20932766]
HT-29	IC₅₀	80.09 μM Compound: GA	Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
HeLa	IC₅₀	> 100 μM Compound: GA	Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
HeLa	IC₅₀	> 40 μM Compound: GA	Antiproliferative activity against human HeLa cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 72 hrs by MTT assay	[PMID: 31226654]
HepG2	IC₅₀	44.51 μM Compound: GA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30528976]
HepG2	IC₅₀	81.42 μM Compound: GA	Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay	[PMID: 37742398]
HepG2	IC₅₀	94.45 μM Compound: GA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29486954]
HepG2	IC₅₀	> 20 μM Compound: 2; Glycyrrhetic acid	Antiproliferative activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C4MD00344F
HepG2	IC₅₀	> 40 μM Compound: GA	Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 31226654]
HepG2	IC₅₀	> 50 μM Compound: GA	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 20932754]
HepG2 2.2.15	CC₅₀	55.15 μM Compound: GA	Cytotoxicity against human HepG2(2.2.15) cells Cytotoxicity against human HepG2(2.2.15) cells	[PMID: 22520261]
HepG2 2.2.15	CC₅₀	650 μM Compound: B1; GA	Cytotoxicity against human HepG2.215 cells assessed as reduction in cell viability after 3 days by MTT assay Cytotoxicity against human HepG2.215 cells assessed as reduction in cell viability after 3 days by MTT assay	[PMID: 29627260]
HepG2 2.2.15	IC₅₀	130.49 μM Compound: GA	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in hepatitis B e-antigen release Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in hepatitis B e-antigen release	[PMID: 22520261]
HepG2 2.2.15	IC₅₀	20.86 μM Compound: GA	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in hepatitis B surface antigen release Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in hepatitis B surface antigen release	[PMID: 22520261]
HepG2 2.2.15	IC₅₀	39.28 μM Compound: GA	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA replication Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA replication	[PMID: 22520261]
Hs 683	GI₅₀	84 μM Compound: 1, GA	Growth inhibition in apoptosis-sensitive human Hs683 after 3 days by MTT assay Growth inhibition in apoptosis-sensitive human Hs683 after 3 days by MTT assay	[PMID: 21888390]
K562	IC₅₀	> 200 μM Compound: 3; GA	Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
K562/Adr	IC₅₀	86.46 μM Compound: 3; GA	Cytotoxicity against human K562/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human K562/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
KB	ED₅₀	> 21 μM Compound: 1, GA	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 17591444]
KB	GI₅₀	61.2 μM Compound: 1, GA	Growth inhibition of human KB cells by SRB assay Growth inhibition of human KB cells by SRB assay	[PMID: 23122524]
L02	IC₅₀	> 200 μM Compound: 3; GA	Cytotoxicity against human LO2 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
L02	IC₅₀	> 200 μM Compound: GA	Cytotoxicity against human HL7702 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay	[PMID: 37742398]
L02	IC₅₀	> 50 μM Compound: GA	Antiproliferative activity against human HL-7702 cells after 48 hrs by MTT assay Antiproliferative activity against human HL-7702 cells after 48 hrs by MTT assay	[PMID: 30528976]
LNCaP	ED₅₀	> 21 μM Compound: 1, GA	Cytotoxicity against human LN-Cap cells Cytotoxicity against human LN-Cap cells	[PMID: 17591444]
MCF7	EC₅₀	84.7 μM Compound: GA	Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
MCF7	EC₅₀	> 30 μM Compound: 3	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 28033541]
MCF7	EC₅₀	> 30 μM Compound: GA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
MCF7	GI₅₀	76 μM Compound: 1, GA	Growth inhibition in apoptosis-sensitive human MCF7 after 3 days by MTT assay Growth inhibition in apoptosis-sensitive human MCF7 after 3 days by MTT assay	[PMID: 21888390]
MCF7	IC₅₀	32.6 μM Compound: 18betaH-GA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by ATP based luminometry Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by ATP based luminometry	[PMID: 33383441]
MCF7	IC₅₀	74.75 μM Compound: GA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29486954]
MCF7	IC₅₀	84.7 μM Compound: GA	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 20932766]
MCF7	IC₅₀	84.7 μM Compound: GA	Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
MCF7	IC₅₀	> 100 μM Compound: GA	Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
MCF7	IC₅₀	> 200 μM Compound: 3; GA	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
MCF7	IC₅₀	> 40 μM Compound: GA	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31226654]
MDA-MB-231	IC₅₀	146.6 μM Compound: 1; GA	Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
MDCK	CC₅₀	7.4 μg/mL Compound: Glycyrrhetinic acid	Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs	[PMID: 36455358]
MDCK	IC₅₀	> 40 μM Compound: GA	Cytotoxicity against MDCK cells incubated for 72 hrs by MTT assay Cytotoxicity against MDCK cells incubated for 72 hrs by MTT assay	[PMID: 31226654]
MG-63	IC₅₀	> 50 μM Compound: GA	Antiproliferative activity against human MG63 cells after 48 hrs by MTT assay Antiproliferative activity against human MG63 cells after 48 hrs by MTT assay	[PMID: 30528976]
MGC-803	IC₅₀	> 200 μM Compound: GA	Cytotoxicity against human MGC-803 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay Cytotoxicity against human MGC-803 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay	[PMID: 37742398]
MGC-803	IC₅₀	> 50 μM Compound: GA	Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 30528976]
MIA PaCa-2	IC₅₀	> 20 μM Compound: 2; Glycyrrhetic acid	Antiproliferative activity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C4MD00344F
NCI-H460	IC₅₀	37.65 μM Compound: GA	Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 30528976]
NCI-H460	IC₅₀	62 μg/mL Compound: GA	Cytotoxicity against human NCI-H460 cells assessed as cell viability after 24 hrs by XTT assay Cytotoxicity against human NCI-H460 cells assessed as cell viability after 24 hrs by XTT assay	[PMID: 24461294]
NCI/ADR-RES	IC₅₀	74.49 μM Compound: 3; GA	Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
NIH3T3	EC₅₀	18.7 μM Compound: 3	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 28033541]
NIH3T3	EC₅₀	18.7 μM Compound: GA	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
NIH3T3	IC₅₀	18.52 μM Compound: GA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 20932766]
NTUB1	IC₅₀	27.31 μM Compound: 1, 18beta-GA, GA	Cytotoxicity against human NTUB1 cells after 72 hrs by MTT assay Cytotoxicity against human NTUB1 cells after 72 hrs by MTT assay	[PMID: 21696969]
PANC-1	IC₅₀	132.2 μM Compound: 1; GA	Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
PC-12	EC₅₀	0.89 μM Compound: 2	Neuroprotective activity against CoCl2-induced neuronal injury in rat PC12 cells Neuroprotective activity against CoCl2-induced neuronal injury in rat PC12 cells	[PMID: 31924497]
PC-3	ED₅₀	> 21 μM Compound: 1, GA	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 17591444]
PC-3	GI₅₀	80 μM Compound: 1, GA	Growth inhibition in apoptosis-sensitive human PC3 after 3 days by MTT assay Growth inhibition in apoptosis-sensitive human PC3 after 3 days by MTT assay	[PMID: 21888390]
PC-3	GI₅₀	95.72 μM Compound: GA	Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay	[PMID: 28838831]
PC-3	IC₅₀	105.24 μM Compound: GA	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 31883490]
PC-3	IC₅₀	> 20 μM Compound: 2; Glycyrrhetic acid	Antiproliferative activity against human PC3 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C4MD00344F
RAW264.7	IC₅₀	1.3 μM Compound: 3	Inhibition of LPS-induced TNFalpha release in mouse RAW264.7 cells pretreated 1 hr before LPS challenge by enzyme immunoassay Inhibition of LPS-induced TNFalpha release in mouse RAW264.7 cells pretreated 1 hr before LPS challenge by enzyme immunoassay	[PMID: 19278854]
RAW264.7	IC₅₀	187.88 μM Compound: GA	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 2 hrs prior to LPS-challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 2 hrs prior to LPS-challenge measured after 24 hrs by Griess method	[PMID: 23373965]
Raji	IC₅₀	> 80 μM Compound: Glycyrrhetic acid	Cytotoxicity against human Raji cells assessed as cell viability at 0.32 nmol after 48 hrs by trypan blue assay Cytotoxicity against human Raji cells assessed as cell viability at 0.32 nmol after 48 hrs by trypan blue assay	[PMID: 12608850]
SK-MEL-28	GI₅₀	92 μM Compound: 1, GA	Growth inhibition in apoptosis-resistant human SK-MEL-28 after 3 days by MTT assay Growth inhibition in apoptosis-resistant human SK-MEL-28 after 3 days by MTT assay	[PMID: 21888390]
SK-OV-3	IC₅₀	45.62 μM Compound: GA	Growth inhibition of cisplatin sensitive human SKOV3 cells after 48 hrs by MTT assay Growth inhibition of cisplatin sensitive human SKOV3 cells after 48 hrs by MTT assay	[PMID: 30528976]
SW-1736	IC₅₀	76.93 μM Compound: GA	Cytotoxicity against human SW1736 cells after 96 hrs by SRB assay Cytotoxicity against human SW1736 cells after 96 hrs by SRB assay	[PMID: 20932766]
SW-1736	IC₅₀	76.93 μM Compound: GA	Cytotoxicity against human SW1736 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human SW1736 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
SW480	IC₅₀	86.8 μM Compound: GA	Cytotoxicity against human SW480 cells after 96 hrs by SRB assay Cytotoxicity against human SW480 cells after 96 hrs by SRB assay	[PMID: 20932766]
SW480	IC₅₀	86.8 μM Compound: GA	Cytotoxicity against human SW480 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human SW480 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
Sf21	IC₅₀	> 40 μM Compound: 7	Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis	[PMID: 31774676]
T-24	IC₅₀	56.78 μM Compound: GA	Cytotoxicity against human T24 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay Cytotoxicity against human T24 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay	[PMID: 37742398]
T98G	GI₅₀	85 μM Compound: 1, GA	Growth inhibition in apoptosis-resistant human T98G after 3 days by MTT assay Growth inhibition in apoptosis-resistant human T98G after 3 days by MTT assay	[PMID: 21888390]
U-373MG ATCC	GI₅₀	83 μM Compound: 1, GA	Growth inhibition in apoptosis-resistant human U373 after 3 days by MTT assay Growth inhibition in apoptosis-resistant human U373 after 3 days by MTT assay	[PMID: 21888390]

In Vitro

18β-Glycyrrhetinic acid is the major bioactive component of Glycyrrhizae Radix and possesses anti-ulcerative, anti-inflammatory and antiproliferative properties. MTS assay demonstrates that 24 h treatment of 18β-Glycyrrhetinic acid suppresses cell proliferation in both cell lines in a dose-dependent manner. 18β-Glycyrrhetinic acid at 160 μM significantly decreases the percentage of viable cells to around 40.5±10.5% in A549 and 38.3±4.6% in NCI-H460 (p<0.01 respectively). When the cells are treated with 320 μM 18β-Glycyrrhetinic acid, a greater inhibitory effects on cell proliferation is shown, as the percentage of viable cells is below 30% compare with untreated controls (p<0.001). Treatment with 18β-Glycyrrhetinic acid at 160 μM and 320 μM decreases the levels of full-length PARP and increases the levels of cleaved-PARP^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Rats in 18β-Glycyrrhetinic acid+Triptolide (TP) group which receive low-dose 18β-Glycyrrhetinic acid (50 mg/kg) have significant reductions in the three serum parameters when compare with TP rats. Rats in 18β-Glycyrrhetinic acid+TP group which receive the high-dose 18β-Glycyrrhetinic acid (100 mg/kg) have slightly lowered the levels of three liver enzymes, the reductions do not reach statistical significance compare with TP group. Contrastingly, preadministration of low-dose 18β-Glycyrrhetinic acid protects animals from TP-induced hepatic lesions. On the contrary, low-dose 18β-Glycyrrhetinic acid (50 mg/kg) markedly suppresses the release of the four cytokines above^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

470.68

Formula

C₃₀H₄₆O₄

CAS No.

471-53-4

Appearance

Solid

Color

White to off-white

SMILES

CC1(C)[C@@H](O)CC[C@]([C@@]1([H])CC[C@@]([C@@]2(CC[C@]3(CC[C@](C(O)=O)(C[C@]3(C2=C4)[H])C)C)C)5C)(C)[C@@]5([H])C4=O

Structure Classification

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : 116.67 mg/mL (247.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1246 mL	10.6229 mL	21.2459 mL
5 mM	0.4249 mL	2.1246 mL	4.2492 mL
10 mM	0.2125 mL	1.0623 mL	2.1246 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.17 mg/mL (4.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.17 mg/mL (4.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 25 mg/mL (53.11 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.88%

Select Batch:

Data Sheet (285 KB) SDS (393 KB)

COA (256 KB) LCMS (274 KB)

Handling Instructions (2659 KB)

References

[1]. Huang RY, et al. 18β-Glycyrrhetinic acid suppresses cell proliferation through inhibiting thromboxane synthase in non-small cell lung cancer. PLoS One. 2014 Apr 2;9(4):e93690. [Content Brief]

[2]. Zhou J, et al. 18β-glycyrrhetinic acid suppresses experimental autoimmune encephalomyelitis through inhibition of microglia activation and promotion of remyelination. Sci Rep. 2015 Sep 2;5:13713. [Content Brief]

[3]. Yang G, et al. Protective Effect of 18β-Glycyrrhetinic Acid against Triptolide-Induced Hepatotoxicity in Rats. Evid Based Complement Alternat Med. 2017;2017:3470320. [Content Brief]

Cell Assay ^[2]	Primary microglia cultures are used in this study. For treatment assay, microglia are incubated with complete DMEM and stimulated with or without 100 ng/mL IFN-γ in the presence or absence of 18β-Glycyrrhetinic acid (25 μM and 50 μM) at 37°C in a humidified incubator with 5% CO₂. For cell migration assay, the isolated primary microglia that seeded in complete DMEM medium are stimulated with or without IFN-γ (100 ng/mL), and treated with different doses of 18β-Glycyrrhetinic acid, 24 h later, the microglia culture supernatants are collected and added to the lower chambers of Transwell inserts^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Healthy Wistar rats (male, 200±20 g) are used and divided into five groups with 10 individuals for each group randomly. Animals in normal control (NC) group receive distilled water for 6 days and 0.5% CMC-Na for the last 3 days. Rats in Triptolide model group (TP), 18β-Glycyrrhetinic acid low-dose group (GAL+TP), and 18β-Glycyrrhetinic acid high-dose group (GAH+TP) receive distilled water, 18β-Glycyrrhetinic acid (50 mg/kg, p.o., dissolved in distilled water), or 18β-Glycyrrhetinic acid (100 mg/kg, p.o., dissolved in distilled water) for consecutive 6 days, respectively, and liver injury is induced by TP (2.4 mg/kg, p.o., suspended in 0.5% CMC-Na) for the last 3 days. Animals in the above three groups receive TP 6 hours after distilled water or 18β-Glycyrrhetinic acid treatment on the last 3 days^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Huang RY, et al. 18β-Glycyrrhetinic acid suppresses cell proliferation through inhibiting thromboxane synthase in non-small cell lung cancer. PLoS One. 2014 Apr 2;9(4):e93690. [Content Brief] [2]. Zhou J, et al. 18β-glycyrrhetinic acid suppresses experimental autoimmune encephalomyelitis through inhibition of microglia activation and promotion of remyelination. Sci Rep. 2015 Sep 2;5:13713. [Content Brief] [3]. Yang G, et al. Protective Effect of 18β-Glycyrrhetinic Acid against Triptolide-Induced Hepatotoxicity in Rats. Evid Based Complement Alternat Med. 2017;2017:3470320. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1246 mL	10.6229 mL	21.2459 mL	53.1146 mL
	5 mM	0.4249 mL	2.1246 mL	4.2492 mL	10.6229 mL
	10 mM	0.2125 mL	1.0623 mL	2.1246 mL	5.3115 mL
	15 mM	0.1416 mL	0.7082 mL	1.4164 mL	3.5410 mL
	20 mM	0.1062 mL	0.5311 mL	1.0623 mL	2.6557 mL
	25 mM	0.0850 mL	0.4249 mL	0.8498 mL	2.1246 mL
	30 mM	0.0708 mL	0.3541 mL	0.7082 mL	1.7705 mL
	40 mM	0.0531 mL	0.2656 mL	0.5311 mL	1.3279 mL
	50 mM	0.0425 mL	0.2125 mL	0.4249 mL	1.0623 mL
	60 mM	0.0354 mL	0.1770 mL	0.3541 mL	0.8852 mL
	80 mM	0.0266 mL	0.1328 mL	0.2656 mL	0.6639 mL
	100 mM	0.0212 mL	0.1062 mL	0.2125 mL	0.5311 mL